WO2002046772A1 - Detection de composes tels que la thyroxine - Google Patents

Detection de composes tels que la thyroxine Download PDF

Info

Publication number
WO2002046772A1
WO2002046772A1 PCT/AU2001/001583 AU0101583W WO0246772A1 WO 2002046772 A1 WO2002046772 A1 WO 2002046772A1 AU 0101583 W AU0101583 W AU 0101583W WO 0246772 A1 WO0246772 A1 WO 0246772A1
Authority
WO
WIPO (PCT)
Prior art keywords
analyte
agent
screening
affinity
thyroxine
Prior art date
Application number
PCT/AU2001/001583
Other languages
English (en)
Inventor
Enzo Ranieri
Peter Sharp
Peter Meikle
Original Assignee
Women's And Children's Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Women's And Children's Hospital filed Critical Women's And Children's Hospital
Priority to AU2002221319A priority Critical patent/AU2002221319A1/en
Publication of WO2002046772A1 publication Critical patent/WO2002046772A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/78—Thyroid gland hormones, e.g. T3, T4, TBH, TBG or their receptors

Definitions

  • the preferred screening method for CHT is the simultaneous measurement of T 4 and TSH analytes on each filter paper blood-spot specimen, as that ensures higher detection rates and lower recall rates and false positive results.
  • the said agent having affinity for said analyte is selected from the group consisting of globulin proteins, monoclonal or polyclonal antibodies, sera, aptomers and antibody or receptor fragments; or derivatives thereof.
  • This process virtually overcomes the problems of signal suppression encountered when determining and quantifying of LMW compounds particularly at concentrations below l ⁇ M from biological samples such as dried blood-spots.
  • the process can be applied to mass newborn screening for the purpose of identifying individuals determined to be at increased risk as a result of the concentration of T 4 that is below or above a population threshold resulting in the need of medical intervention and further specialised diagnostic testing.
  • steps two and three the additives of high affinity binding agents such as monoclonal antibodies, displacer agent, such as saliclyate and stable isotope internal standards are added to the reaction vessel within an aqueous buffered solution using an automated sample delivery equipment.
  • high affinity binding agents such as monoclonal antibodies, displacer agent, such as saliclyate and stable isotope internal standards
  • Table 1 a comparison is provided showing the signal intensities of T 4 by MS /MS with and without derivatisation T4.
  • This increase in signal intensity enables the determination of T 4 to a concentration of 15nM, which is 10 times above the signal to noise ratio.
  • Optimisation of the MS/MS had been performed for both the T 4 butyl ester and underivatised native T4..

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention porte sur un nouveau procédé de spectrométrie de masse de capture simultanée de plusieurs analytes utilisé dans la quantification d'analytes, notamment la thyroxine (T4) et 17-α-hydroxyprogestérone (17OHP), se trouvant dans des taches de sang séché de nouveau-nés afin de procéder à un dépistage de masse et au diagnostic de l'hypothyroïdie congénitale et de l'hyperplasie surrénale congénitale. Ce procédé met en oeuvre un traitement à haut rendement et automatisé prévu pour être totalement intégré aux programmes de dépistage néonatal. L'invention porte également sur un kit de test permettant de réaliser ce procédé.
PCT/AU2001/001583 2000-12-08 2001-12-10 Detection de composes tels que la thyroxine WO2002046772A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002221319A AU2002221319A1 (en) 2000-12-08 2001-12-10 Detection of compounds such as thyroxine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPR1959A AUPR195900A0 (en) 2000-12-08 2000-12-08 Detection of compounds such as thyroxine
AUPR1959 2000-12-08

Publications (1)

Publication Number Publication Date
WO2002046772A1 true WO2002046772A1 (fr) 2002-06-13

Family

ID=3825994

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2001/001583 WO2002046772A1 (fr) 2000-12-08 2001-12-10 Detection de composes tels que la thyroxine

Country Status (2)

Country Link
AU (2) AUPR195900A0 (fr)
WO (1) WO2002046772A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004090553A1 (fr) * 2003-04-14 2004-10-21 Georgetown University Analyse d'hormones thyroïdiennes par spectrométrie de masse
EP1872120A2 (fr) * 2005-03-31 2008-01-02 Georgetown University Analyse de thyroxine libre et de triiodothyronine libre par spectrometrie de masse
WO2008057866A2 (fr) * 2006-11-01 2008-05-15 Pediatrix Medical Group, Inc. Mesurer les teneurs en thyroxine provenant d'échantillons de sang séché à l'aide de la spectrométrie de masse
US8158435B2 (en) 2007-05-04 2012-04-17 Oregon Health & Science University Tandem mass spectrometry for detecting and/or screening for conditions associated with altered sterols
CN106841427A (zh) * 2016-12-30 2017-06-13 广州市达瑞生物技术股份有限公司 一种检测pku和cah的串联质谱试剂盒制备及其应用
CN113933412A (zh) * 2021-09-24 2022-01-14 广州金域医学检验中心有限公司 一种血液中类固醇激素的检测方法
CN114047277A (zh) * 2022-01-10 2022-02-15 天津云检医学检验所有限公司 用于预测早产的尿液代谢物特征及早产预测试剂盒

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
C. DEZATEUX: "Evaluating newborn screening programmes based on dried blood spots: future challenges", BRITISH MEDICAL BULLETIN, vol. 54, no. 4, 1998 *
MILLER S.A. ET AL.: "Chemiluminescence immunoassay for progesterone in plasma incorporating acridinium ester labelled antigen", ANN. CLIN. BIOCHEM., vol. 25, 1988, pages 27 - 34 *
YONG A. ET AL.: "Diagnosis of 21-hydroxylase deficiency in newborn infants by GC-MS of urinary steroids", AUST. PAEDIATR. J., vol. 24, 1988, pages 280 - 285 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE44401E1 (en) 2003-04-14 2013-07-30 Georgetown University Thyroid hormone analysis by mass spectrometry
US7618827B2 (en) 2003-04-14 2009-11-17 Georgetown University Thyroid hormone analysis by mass spectrometry
WO2004090553A1 (fr) * 2003-04-14 2004-10-21 Georgetown University Analyse d'hormones thyroïdiennes par spectrométrie de masse
EP1872120A2 (fr) * 2005-03-31 2008-01-02 Georgetown University Analyse de thyroxine libre et de triiodothyronine libre par spectrometrie de masse
EP1872120A4 (fr) * 2005-03-31 2009-04-29 Univ Georgetown Analyse de thyroxine libre et de triiodothyronine libre par spectrometrie de masse
US8227259B2 (en) 2005-03-31 2012-07-24 Georgetown University Free thyroxine and free triiodothyronine analysis by mass spectrometry
WO2008057866A2 (fr) * 2006-11-01 2008-05-15 Pediatrix Medical Group, Inc. Mesurer les teneurs en thyroxine provenant d'échantillons de sang séché à l'aide de la spectrométrie de masse
WO2008057866A3 (fr) * 2006-11-01 2008-07-03 Pediatrix Medical Group Inc Mesurer les teneurs en thyroxine provenant d'échantillons de sang séché à l'aide de la spectrométrie de masse
US8158435B2 (en) 2007-05-04 2012-04-17 Oregon Health & Science University Tandem mass spectrometry for detecting and/or screening for conditions associated with altered sterols
CN106841427A (zh) * 2016-12-30 2017-06-13 广州市达瑞生物技术股份有限公司 一种检测pku和cah的串联质谱试剂盒制备及其应用
CN106841427B (zh) * 2016-12-30 2019-05-14 广州市达瑞生物技术股份有限公司 一种检测pku和cah的串联质谱试剂盒
CN113933412A (zh) * 2021-09-24 2022-01-14 广州金域医学检验中心有限公司 一种血液中类固醇激素的检测方法
CN113933412B (zh) * 2021-09-24 2023-04-07 广州金域医学检验中心有限公司 一种血液中类固醇激素的检测方法
CN114047277A (zh) * 2022-01-10 2022-02-15 天津云检医学检验所有限公司 用于预测早产的尿液代谢物特征及早产预测试剂盒

Also Published As

Publication number Publication date
AUPR195900A0 (en) 2001-01-04
AU2002221319A1 (en) 2002-06-18

Similar Documents

Publication Publication Date Title
JP7399200B2 (ja) 質量分析によるインスリンの定量
JP6538004B2 (ja) 質量分析によってジヒドロキシビタミンｄ代謝物を検出するための方法
US11280798B2 (en) Methods for detecting estrone by mass spectrometry
US20080176333A1 (en) Analysis of Proteins from Biological Fluids Using Mass Spectrometric Immunoassay
US20100273178A1 (en) Affinity selected signature peptides for protein identification and quantification
JP2007101559A (ja) 多種検定用の標準希釈液
JP2000508075A (ja) 発光特異的結合アッセイ
US20140361156A1 (en) Methods for Simultaneous Quantification of Thyroid Hormones and Metabolites Thereof by Mass Spectrometry
JP3424831B2 (ja) 結合アッセイ
US7396687B2 (en) Mass spectrometric immunoassay analysis of specific proteins and variants present in various biological fluids
US20070166766A1 (en) Method and apparatus for mass spectrometric immunoassay analysis of specific biological fluid proteins
FI111194B (fi) Kaksikohtainen immuunitesti vasta-aineelle käyttäen kemiluminisoivaa leimaa ja biotiiniin sidottua ligandia
WO2002046772A1 (fr) Detection de composes tels que la thyroxine
US20050191677A1 (en) Mass spectrometric concentration measurement of proteins
Sogawa et al. The measurement of a fibrinogen α C-chain 5.9 ákDa fragment (FIC 5.9) using MALDI-TOF MS and a stable isotope-labeled peptide standard dilution
CN116106559A (zh) 一种生物素与抗体偶联比检测试剂盒及其应用
CN116559333B (zh) 一种外泌体表面蛋白绝对定量的方法及其应用
US20230273217A1 (en) Derivatization of at least one analyte of interest for mass spec measurements in patient samples
Suckau et al. An automated assay for the clinical measurement of plasma renin activity by immuno-MALDI (iMALDI)☆
Quinn et al. SIMULTANEOUS QUANTITATION OF SPECIFIC PROTEINS USING IMMUNO-ASSAY ICP-MS
AU2002232578A1 (en) Standard diluent for multiplex assays

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP